Lori Anne Kunkel, Director of Enliven Therapeutics (NASDAQ:ELVN), reported the sale of 10,000 shares of common stock for a total consideration of approximately $345,000 on June 5, 2026, according to a SEC Form 4 filing.
Transaction summary
Transaction value based on SEC Form 4 weighted average purchase price ($34.54); post-transaction value based on June 5, 2026 market close.
Key questions
How does this transaction align with Kunkel’s historical trading activity?
This sale marks Kunkel’s first open-market disposition of Enliven Therapeutics common stock, following a history of administrative filings with no prior open-market sales reported.What portion of Kunkel’s total direct holdings was affected?
The transaction represented 16% of her direct common stock holdings, reducing her stake from 61,884 to 51,884 shares, with no impact on any indirect or derivative positions.Was the transaction executed under a pre-arranged plan?
Yes, the Form 4 notes that the sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.What is the market context for this sale?
As of June 5, 2026, Enliven Therapeutics shares had returned 62.4% over the prior year, and the transaction was completed at a weighted average price of $34.54, with the stock closing at $34.71 on the transaction date and subsequently appreciating to $50 by Friday.
Company overview
Company snapshot
Enliven Therapeutics develops small molecule kinase inhibitors, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2-mutant cancers; both candidates are in Phase 1 clinical trials.
The firm operates a clinical-stage biopharmaceutical model focused on advancing proprietary oncology therapeutics through early-stage development, with future revenue expected from product commercialization or strategic partnerships.
It targets oncologists, cancer treatment centers, and biopharma partners addressing unmet needs in hematologic and solid tumor oncology markets.
Enliven Therapeutics is a Boulder-based biotechnology company specializing in the discovery and clinical development of novel small-molecule therapies for cancer. With a lean workforce and a focus on kinase inhibitors, the company aims to address high-value oncology indications with significant unmet need. Enliven’s competitive edge lies in its targeted approach and advancement of differentiated assets in early-stage clinical trials.
